Partial
Mostly Aligned
Patient Risk:
Low
Summary
Several AI claims align with label sections (indication, description, mechanism reducing evaporation, and blurred vision being the most common adverse reaction with 1–3% reporting). However, multiple claims are not fully supported or are inaccurate relative to the label provided (notably dosing frequency, OTC status, and several specific adverse-reaction incidence statements).
Category Scores
Accurate Statements
Miebo is a prescription eye drop used to treat the signs and symptoms of dry eye disease.
Label section 1 INDICATIONS AND USAGE: indicated for treatment of signs and symptoms of dry eye disease (DED). (Label text provided does not explicitly say “prescription” but being an ophthalmic solution indicated in label supports use; prescription status not explicitly provided.)
Miebo is designed to reduce tear evaporation.
Label 12.1: Perfluorohexyloctane forms a monolayer at the air-liquid interface of the tear film which can be expected to reduce evaporation.
Miebo works by reducing tear evaporation.
Label 12.1: expected to reduce evaporation (mechanistic statement).
The active ingredient of Miebo, perfluorohexyloctane, is a non-aqueous solution.
Label 11 DESCRIPTION: 100% perfluorohexyloctane; practically immiscible with water.
Perfluorohexyloctane spreads evenly across the ocular surface.
Not directly supported by the provided label text.
Miebo forms a protective layer that helps reduce evaporation from the tear film.
Label 12.1: forms a monolayer at the air-liquid interface of the tear film expected to reduce evaporation. (“Protective layer” wording not exact but is consistent with monolayer concept.)
Reducing evaporation from the tear film alleviates the dryness associated with dry eye disease.
Not explicitly stated in provided label text; label indicates reduction in evaporation is expected, and indication is for signs/symptoms of DED, but the causal phrasing “alleviates dryness” is not explicitly provided.
The most common ocular adverse reaction reported with Miebo is blurred vision.
Label 6.1: “The most common ocular adverse reaction was blurred vision.”
Other less common side effects of Miebo may include eye stinging or burning.
Not supported by the provided label text.
Other less common side effects of Miebo may include discharge from the eye.
Not supported by the provided label text.
Other less common side effects of Miebo may include reduced visual acuity.
Not supported by the provided label text.
Traditional artificial tears are often water-based and may evaporate quickly.
Not supported by the provided label text.
Miebo's non-aqueous formulation aims for a longer-lasting effect on the tear film.
Partially supported: label states practically immiscible with water and monolayer reduces evaporation, but “longer-lasting effect” is not explicitly stated in provided text.
Unsupported Statements
Perfluorohexyloctane spreads evenly across the ocular surface.
Provided label text does not state even spreading across the ocular surface.
Reducing evaporation from the tear film alleviates the dryness associated with dry eye disease.
Label provides indication and an expected reduction in evaporation, but does not explicitly link evaporation reduction to alleviating dryness in the provided excerpt.
Blurred vision occurs in 1-5% of users with Miebo.
Label 6.1 states blurred vision reported in 1–3% of individuals (not 1–5%).
Other less common side effects of Miebo may include eye stinging or burning.
Provided label text does not list stinging/burning.
Other less common side effects of Miebo may include discharge from the eye.
Provided label text does not list discharge.
Other less common side effects of Miebo may include reduced visual acuity.
Provided label text does not list reduced visual acuity.
Miebo differentiates from many other dry eye treatments that focus on increasing tear production or providing lubrication by targeting tear evaporation.
Provided label text does not include comparative differentiation against other treatments.
Traditional artificial tears are often water-based and may evaporate quickly.
Provided label text does not describe traditional artificial tear composition or evaporation.
Miebo's non-aqueous formulation aims for a longer-lasting effect on the tear film.
Provided label text supports monolayer reducing evaporation but does not explicitly claim a “longer-lasting effect.”
Miebo is not available over-the-counter and requires a doctor's order to obtain.
Provided label excerpts do not explicitly state OTC vs prescription status.
Contradictions
Low
AI Statement
Blurred vision occurs in 1-5% of users with Miebo.
Label Reference
Label 6.1: Blurred vision and conjunctival redness were reported in 1-3% of individuals.
Important Omissions
Dosage and administration details (e.g., instill one drop four times daily) were not mentioned in the AI claims provided, though label includes patient counseling instruction to instill one drop four times daily and contact lens guidance.
Importance:
Moderate
Contact lens handling instruction (remove prior to and for at least 30 minutes after administration) was not included in the AI claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Main safety-related alignment is that blurred vision is the most common ocular adverse reaction and low-percentage reporting is consistent; however, the incidence range (1–5% vs label 1–3%) and several unsupported adverse-reaction claims could mislead risk perception.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Several claims are not supported by the provided label text, and one adverse-reaction incidence statement (blurred vision 1–5%) contradicts the label excerpt (1–3%).
Suggested Improvement
Remove or revise unsupported mechanistic/comparative and additional side-effect claims; correct blurred vision incidence to 1–3% as stated. If including dosing/administration, cite label instruction (one drop four times daily; contact lens removal for at least 30 minutes).